 |
Page History
...
| Committee Member | Present | Absent |
|---|---|---|
| X | ||
| Toby Hecht | X | |
| X | ||
| X | ||
| Elaine Ostrander | X | |
| Deborah Knapp | X | |
| Jeff Trent | X | |
| Dawn Duval | X | |
| Amy Leblanc | X | |
| Heather Gardner | X | |
| Cheryl London | X | |
| Christina Mazcko | X | |
| Paula Jacobs | X | |
| Renee Chambers | X | |
| Shaying Zhao | X | |
| Sunetra Das | X |
Outstanding Action Items
- Kuffel, Gina (NIH/NCI) [C] to start 2 docs, 1 for items to track for standardization, 1 for the letter to move the needle on canFam4 annotations.
- Toby to reach out to Connie about extending invite to new PRECINCT members.
- Jeff Trent to provide final review of BPSC manuscript.
...
| Agenda Item | Who | Notes |
|---|---|---|
| Sunsetting or Repurposing the BPSC | Group Discussion | |
First New ICDC Subcommittee: Longitudinal Data Acquisition and Use Committee (LDAUC) Purpose: Formulate scientific questions and use cases that can be used to interrogate longitudinal datasets that would justify the ingestion of such data into the ICDC. | Group Discussion |
|
Second New ICDC Subcommittee: Cross-Species Mapping Committee (CSMC) | Group Discussion |
|
Meeting Minutes (Not Verbatim)
TH - Wrapping up 5 years of the ICDC. New options begin on September 24, 2023. Lets think about if we still need this committee and what are the specifics that we want to tackle in the next 5 years. Once everything is signed off on, we need to send everyone a copy of the statement of work. Do we still need this committee and do we need additional expertise? We don't need to make decisions today, but we need to begin thinking about this.
JT - The field is changing, many players will be making contributions from a genomic perspective. There is value in a harmonized analysis framework structurally in comparable human resources.
TH - The next 5 years will focus on the usability of the repos within the CRDC (PDC, CTDC, GDC). Important for comparative oncology. If we can get additional people who are fluent in this type of analysis, we have not approached this yet. Data analysis and structural differences can pose issues.
PJ - Data are more valuable if there are clearly comparable from study to study, especially in regards to histology.
TH - Do we want to invite someone else to augment expertise and provide guidance.
AL - PetCT consortium fell apart for a little bit due to personnel change. I've joined forces to help consortium-based data standards. We've reached out to radiologists to see if we can have consensus for a core set of sequences important to brain cancer, but there is pushback at times without a structured driver.
PJ - Biggest pushback came from the most advanced centers. We made a protocol that defined a core and allowed for flexibility beyond that. On the human side I can bring in a couple of people.
...
PJ - Take another look that groups are harmonizing in a way that is consistent.
JT - There is a suite of new approaches whether single cell, spatial, long reads, etc. The data normalization that is required needs standardization.
CL - I will take the chair of this committee. I made all corrections to final draft of the BPSC article, can someone take one last final look?
JT - I would be happy to.
...
Meeting Minutes (Not Verbatim
...
TH - Let's think about repurposing this committee or augmenting the scope of this committee
CL - Issues with integrity of RNA and frozen specimens just as an example, perhaps protocol and data analysis standardizations.
AL - Beginning with nucleic acid extraction, dependent on tissue type, getting a single nuclei out of a real bone tumor, easy to do in mouse and simple tissues, but there are not standard protocols in dog.
TH - Would there be a place in the ICDC for SOPs pertaining to RNA isolation, nucleic acid extraction, library preparation, sequencing methods?
TH - Highlighting differences between human and dog, maybe differences in assay prep could contribute to differences in data
...
)
...
AL - Methylation is a good example, doing this in Osteo right now, low pass whole genome helps to interpret methylation results computationally, this was something that was not known initially.
CL - A roadmap for people that don't always work with canine samples would be helpful so that they are not discouraged.
HG - Availability of analysis pipelines even for working locally.
SZ - Some discussion around canFam4 and annotation
AL - Sample procurement and processing is a good place to start as well as the buckets for analysis mentioned by Heather.
DD - There is talk of a Pan canFam genome
SZ - Genome annotation cannot be done by a single lab, this needs to be a community effort
CL - We can start with simple things such as sample requisition and sample preservation, OCT blocks cannot be used because the RNA is degraded.
HG - Challenges are around RNA quality and it is not high enough to perform 10X spatial transcriptomics. My understanding is that NCBI was going to handle annotations for canFam4, but instead they did the ROS version of the genome instead.
TH - Elaine may be a good contact for reaching out to NCBI
AL - We gained a ton of experience with NanoString from FFPE and how to approach these type of samples for the canine IO profiling assay, garbage in garbage out.
HG - QC has changed for the nCounter
AL - Having a pathologist involved is very important when assessing the integrity of samples, it is no longer RIN
Contacts from Dawn Duval regarding canFam4
Kerstin Lindblad-toh gave me these indivivduals as potential contacts to pressure for annotation of the GSD genome.ENSEMBLE
NCBI
...
Action items
